EME2: A Potential Drug Target and Biomarker (G197342)

Target Name: EME2

NCBI ID: G197342

EME2

EME2: A Potential Drug Target and Biomarker

EME2 (endoplasmic reticulum-associated protein 2) is a protein that is expressed in various tissues and cells throughout the body. It is involved in the transport of proteins across the endoplasmic reticulum, which is the final destination for the majority of newly synthesized proteins. EME2 has also been shown to play a role in the regulation of cellular processes such as cell signaling, apoptosis, and inflammation.

Potential Drug Target

EME2 has been identified as a potential drug target due to its involvement in various cellular processes that are related to human disease. One of the key targets of EME2 is the regulation of cellular signaling pathways, which are involved in many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

EME2 has been shown to play a role in the regulation of several signaling pathways, including the TGF-β pathway, which is involved in the regulation of cell growth, differentiation, and apoptosis. The TGF-β pathway is a well-established target for many drugs that are used to treat cancer, including inhibitors of the TGF-β receptor.

Another potential drug target for EME2 is the regulation of the PI3K/Akt signaling pathway, which is involved in the regulation of cell signaling, inflammation, and metabolism. The PI3K/Akt pathway is a target for many drugs that are used to treat autoimmune disorders, including diseases such as rheumatoid arthritis and psoriasis.

Biomarker

EME2 has also been shown to be a potential biomarker for several diseases, including cancer. The expression of EME2 has been shown to be increased in various tissues and cells of cancer patients, and it has been used as a biomarker for the diagnosis and evaluation of cancer.

One of the key advantages of using EME2 as a biomarker for cancer is its ability to be expressed in a variety of cancer types, including breast, lung, and ovarian cancers. This makes it a potentially useful biomarker for the diagnosis and treatment of many different types of cancer.

Another advantage of EME2 is its stability and expression in different cell types and tissues, which makes it a potentially useful biomarker for the long term monitoring of cancer outcomes. This is because the expression of EME2 is not dependent on the specific type of cancer or the stage of the disease, which makes it a potentially useful biomarker for the long term monitoring of cancer outcomes.

Conclusion

EME2 is a protein that is involved in the regulation of various cellular processes that are related to human disease. Its potential as a drug target and biomarker make it an attractive target for research into the treatment of cancer and other diseases. Further studies are needed to fully understand the role of EME2 in cellular processes and its potential as a drug target and biomarker.

Protein Name: Essential Meiotic Structure-specific Endonuclease Subunit 2

Functions: Interacts with MUS81 to form a DNA structure-specific endonuclease which cleaves substrates such as 3'-flap structures

The "EME2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EME2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets